ARK Genomic Revolution ETF
ARKG
284 hedge funds and large institutions have $609M invested in ARK Genomic Revolution ETF in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 64 increasing their positions, 104 reducing their positions, and 36 closing their positions.
5.9% more ownership
Funds ownership: 31.32% → 37.22% (+5.9%)
5% less funds holding
Funds holding: 298 → 284 (-14)
9% less capital invested
Capital invested by funds: $671M → $609M (-$61.7M)
25% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 36
38% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 104
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
59% less call options, than puts
Call options by funds: $49.5M | Put options by funds: $121M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$35.3M |
| 2 |
JP Morgan Chase
New York
|
+$24M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$15.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.24M |
| 5 |
Citigroup
New York
|
+$7.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$37.4M |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$9.15M |
| 3 |
Goldman Sachs
New York
|
-$8.92M |
| 4 |
Two Sigma Advisers
New York
|
-$7.29M |
| 5 |
Two Sigma Investments
New York
|
-$6.54M |
ARKG Hedge Fund Activity: Q1 2024 in Review
284 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q1 2024, worth a combined $609M — down 9.2% from $671M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ARKG and 27 opened new positions — a net loss of 9 holders — while 104 trimmed existing stakes and 64 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $35.3M. The largest seller was Morgan Stanley, cutting an estimated $37.4M.
- 284 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q1 2024, down from 298 in Q4 2023.
- Funds reported $609M of ARK Genomic Revolution ETF stock for Q1 2024, down 9.2% quarter-over-quarter.
- 27 funds opened new ARK Genomic Revolution ETF positions in Q1 2024 and 36 closed out, a net change of -9 holders.
- The largest ARK Genomic Revolution ETF buyer in Q1 2024 was BNP Paribas Financial Markets, an estimated $35.3M added.
- The largest ARK Genomic Revolution ETF seller in Q1 2024 was Morgan Stanley, an estimated $37.4M sold.
Based on aggregated 13F filings for Q1 2024.